2026 Annual Meeting | C38 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Date Saturday 04/18/26

Time 02:30 PM - 04:30 PM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Samantha Banks, MD

Topic(s) General Neurology

Learning Objectives Participants will be able to evaluate patients presenting with myelopathy and avoid common diagnostic pitfalls. General neurologists will be able to synthesize clinical and radiologic pearls to assist in selecting the correct diagnostic testing and recognizing the cause of myelopathy. Attendees will be aware of advances in the management of inflammatory and vascular myelopathies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
02:30 PM - 02:50 PM CDT	Speaker	Introduction, Overview to the Approach to Myelopathy and Differential Diagnosis Samantha Banks, MD
02:50 PM - 03:30 PM CDT	Speaker	Radiologic Pearls and Acute Management of Autoimmune Myelopathies Eoin P. Flanagan, MBBCh, FAAN
03:30 PM - 04:00 PM CDT	Speaker	Diagnosis and Evaluation of Vascular Myelopathies Paula Barreras, MD
04:00 PM - 04:30 PM CDT	Speaker	Challenging Myelopathy Cases Samantha Banks, MD, Eoin P. Flanagan, MBBCh, FAAN, Paula Barreras, MD

Faculty Disclosures
Samantha Banks, MD	Dr. Banks has nothing to disclose.
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Paula Barreras, MD	The institution of Dr. Barreras has received research support from Foundation for Sarcoidosis Research. The institution of Dr. Barreras has received research support from ��ɫ��.

��ɫ����

��ɫ����

��ɫ��

��ɫ��